Consolidated Statements of Operations - USD ($)	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Revenue
Operating expenses:
General and administrative (including stock-based compensation (Note 8))	3,089,689	1,724,677
Depreciation	1,248	1,314
Research and development (including stock-based compensation (Note 8))	1,123,836	520,084
Total operating expenses	4,214,773	2,246,075
Loss from operations	(4,214,773)	(2,246,075)
Other (income) expense:
Gain on extinguishment of liabilities	(122,423)
Other income	(6,000)
Interest expense, net	466,891	413,057
Total other expense	338,468	413,057
Net loss	(4,553,241)	(2,659,132)
Net loss attributable to the noncontrolling interest	7,506	4,930
Net loss applicable to Bion's common stockholders	$ (4,545,735)	$ (2,654,202)
Net loss applicable to Bion's common stockholders per basic and diluted common share (in dollars per share)	$ (0.16)	$ (0.10)
Weighted-average number of common shares outstanding:
Basic and diluted (in shares)	29,031,106	26,522,326